887 related articles for article (PubMed ID: 29128391)
1. Preclinical models of non-alcoholic fatty liver disease.
Santhekadur PK; Kumar DP; Sanyal AJ
J Hepatol; 2018 Feb; 68(2):230-237. PubMed ID: 29128391
[TBL] [Abstract][Full Text] [Related]
2. Non-alcoholic fatty liver disease (NAFLD) models in drug discovery.
Cole BK; Feaver RE; Wamhoff BR; Dash A
Expert Opin Drug Discov; 2018 Feb; 13(2):193-205. PubMed ID: 29190166
[TBL] [Abstract][Full Text] [Related]
3. Animal models of NAFLD from the pathologist's point of view.
Denk H; Abuja PM; Zatloukal K
Biochim Biophys Acta Mol Basis Dis; 2019 May; 1865(5):929-942. PubMed ID: 29746920
[TBL] [Abstract][Full Text] [Related]
4. Therapies in non-alcoholic steatohepatitis (NASH).
Oseini AM; Sanyal AJ
Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
[TBL] [Abstract][Full Text] [Related]
5. CD44 is a key player in non-alcoholic steatohepatitis.
Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
[TBL] [Abstract][Full Text] [Related]
6. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Wu J
Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
[TBL] [Abstract][Full Text] [Related]
7. Histopathological findings of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Kage M; Aishima S; Kusano H; Yano H
J Med Ultrason (2001); 2020 Oct; 47(4):549-554. PubMed ID: 33136250
[TBL] [Abstract][Full Text] [Related]
8. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
9. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet.
Ikawa-Yoshida A; Matsuo S; Kato A; Ohmori Y; Higashida A; Kaneko E; Matsumoto M
Int J Exp Pathol; 2017 Aug; 98(4):221-233. PubMed ID: 28895242
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges.
Hashimoto E; Tokushige K; Ludwig J
Hepatol Res; 2015 Jan; 45(1):20-8. PubMed ID: 24661406
[TBL] [Abstract][Full Text] [Related]
12. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
[TBL] [Abstract][Full Text] [Related]
13. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
14. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions.
Gerges SH; Wahdan SA; Elsherbiny DA; El-Demerdash E
Life Sci; 2021 Apr; 271():119220. PubMed ID: 33592199
[TBL] [Abstract][Full Text] [Related]
15. An Overview of Mouse Models of Nonalcoholic Steatohepatitis: From Past to Present.
Jacobs A; Warda AS; Verbeek J; Cassiman D; Spincemaille P
Curr Protoc Mouse Biol; 2016 Jun; 6(2):185-200. PubMed ID: 27248434
[TBL] [Abstract][Full Text] [Related]
16. Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.
Jump DB; Lytle KA; Depner CM; Tripathy S
Pharmacol Ther; 2018 Jan; 181():108-125. PubMed ID: 28723414
[TBL] [Abstract][Full Text] [Related]
17. Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis.
Karim G; Bansal MB
touchREV Endocrinol; 2023 May; 19(1):60-70. PubMed ID: 37313239
[TBL] [Abstract][Full Text] [Related]
18. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
[TBL] [Abstract][Full Text] [Related]
19. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases.
Tillman EJ; Rolph T
Front Endocrinol (Lausanne); 2020; 11():601290. PubMed ID: 33381084
[TBL] [Abstract][Full Text] [Related]
20. The diagnosis and treatment of non-alcoholic fatty liver disease.
Altinbas A; Sowa JP; Hasenberg T; Canbay A
Minerva Gastroenterol Dietol; 2015 Sep; 61(3):159-69. PubMed ID: 26080905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
